Fulcrum Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Fulcrum Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2023.
  • Fulcrum Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was $52.5M.
  • Fulcrum Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$32.8M, a 69.5% increase year-over-year.
  • Fulcrum Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$111M, a 1.69% increase from 2022.
  • Fulcrum Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$113M, a 38.9% decline from 2021.
  • Fulcrum Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$81.1M, a 13.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$111M +$1.9M +1.69% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 -$113M -$31.5M -38.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 -$81.1M -$9.44M -13.2% Jan 1, 2021 Dec 31, 2021 10-K/A 2023-06-26
2020 -$71.6M +$12.6M +15% Jan 1, 2020 Dec 31, 2020 10-K/A 2023-06-26
2019 -$84.2M -$50.7M -151% Jan 1, 2019 Dec 31, 2019 10-K/A 2023-06-23
2018 -$33.5M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.